Annovis Bio tweeted today:"We are happy to announce that the data cleaning for our phase II/III study of #buntanetap in #Alzheimers is now completed.
Topline efficacy data is expected in April. $ANVS"
Annovis Bio tweeted today:"We are happy to announce that the data cleaning for our phase II/III study of #buntanetap in #Alzheimers is now completed.
Topline efficacy data is expected in April. $ANVS"
The stock is up 42% on this news. I wonder why they are not mentioning PD in this press release... or is that in a different clinical trial?
This is odd and a little unsettling. I thought the PD trail finished first although I think it was bigger and longer. Clearly no readout then for PD in Q1 2024 as originally indicated.
Good think other news is looking good!
You don't think it's just news for the sake of news? How many other trials have referred to data cleansing?
WTP,
I do think it speaks to Annovis's inexperience. That they are trying to put out some news to counteract the fact that they underestimated the time and effort required to get the data to where it needs to be to have any chance of teasing a signal out of the noise that is UPDRS. I really wish they had done some objective measurement with wearables. The new benchmarks demonstrate that wearables are able to see a firm aggregate signal in 1 year of data.